Denise Myshko

Nearly half of payers not covering GLP-1s for obesity say no price would change their minds on coverage, citing high costs, poor adherence, and weight regain concerns, finds a new survey by PSG.

Pfizer plans 10 phase 3 trials of berobenatide for chronic weight management and obesity-related comorbidities.

Romidepsin is approved to treat adults with cutaneous T-cell lymphoma. Ameal’s generic has received designation for 180 days of exclusivity.

Hospital pharmacy leaders cite a potential rebate model transition for the 340B program as one of their biggest worries amid rising manufacturer restrictions and evolving federal compliance requirements.

Real-world data presented at ASCO also show that at 12 month and 24 months, patients treated with Brukinsa had a higher probability of survival than those treated with other BTK inhibitors.

In an interview before the annual ASCO meeting, Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, talks about NOUS-209, an immunotherapy being studied to prevent cancer in those with Lynch syndrome mutations.

Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, was awarded for his work in cancer immunoprevention and his efforts to develop a cancer vaccine for those who are carriers of Lynch mutations.

Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody that achieved 28-month median survival in advanced squamous non-small cell lung cancer.

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone cancer patients.

A collagen implant that releases radiation after brain tumor surgery reduced cancer recurrence and increased overall survival, according to results presented at ASCO’s annual meeting.

Dana-Farber’s Katherine Janeway, M.D., discusses how molecular biomarkers inform treatment decisions in children and adolescents with the bone cancers Ewing sarcoma and osteosarcoma.

Afrezza is an inhaled insulin and the first needle-free insulin option for children with diabetes.

Hepcludex is an antiviral to treat adults living with chronic hepatitis D virus infection, a serious liver disease that occurs as a co-infection in people with chronic hepatitis B virus.

GLP-1 receptor agonist drugs may reduce cancer progression in lung, breast, colorectal, and liver cancers by 38% to 50%, and high GLP-1 receptor expression correlates with 33% lower mortality risk.

By targeting a specific pathway, the mineralocorticoid receptor, Kerendia is able to stop the cascade of inflammation and fibrosis that leads to kidney disease.

Milliman’s Medical Index finds delivery system consolidation, specialty drug growth, and site-of-care shifts are contributing to employee healthcare costs.

GLP-1 medications, especially for diabetes, will remain an influential cost driver in drug spending this year, supported by broader prescriber adoption and patient demand.

Navitus clients saw prescription drug costs rise 8.4% in 2025, driven by specialty medications, GLP-1s, oncology and dermatology spending.

The FDA approved two new cancer drugs this week, one for rare non-Hodgkin lymphoma and another for elderly acute myeloid leukemia patients.

21 million U.S. adults reported pain disrupting daily life despite having no formal pain-related diagnosis, finds an analysis done by researchers at The University of Texas at Arlington.

Optum Rx will shift to flat, per-member fees by 2027, eliminating spread pricing and passing 100% of drug rebates directly to clients.

Researchers at the University of Texas Health Science Center at Houston have created an organs-on-a-chip system that could provide a way to study pancreatic cancer biology and predict how therapies may perform in patients.

More people stop taking the glucagon-like peptide 1 (GLP-1) drugs for weight loss than is commonly recognized. Insurance coverage is patchy, but for those who do have it, some pharmacy benefit managers have launched programs designed to help keep people keep taking their GLP-1.

A survey from the Business Group on Health finds that employers covering GLP-1 weight loss drugs are reconsidering that coverage in 2027 due to high costs.

MedImpact’s Arpit Patel argues that a focus on net costs instead of rebates could save money for both payers and patients.

CVS Caremark instead will favor the biosimilars Pyzchiva and Yesintek and provide the anti-arthritis drugs for a $0 copay.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of Aug. 25, 2026, for the combination of Tevimbra/Ziihera as a first-line treatment for advanced cancers of the stomach, gastroesophageal junction, and esophagus.

Cebranopadol, a first-in-class dual NOP/MOP receptor agonist, relieves moderate-to-severe acute pain after surgery while reducing abuse risks compared with oxycodone.

Cigna will exit the ACA individual exchange market by 2027 and has already launched Evernorth Signature Pharmacy Benefits Services, a rebate-free PBM model, which will become the standard model for all clients in 2028.